Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Chorea Associated with Huntington’s Disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300077341

Enrollment

Unknown

Registered

2023-11-06

Start date

2023-11-07

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chorea Associated with Huntington’s Disease

Interventions

Adult patients with Huntington's disease related chorea receiving Deutetrabenazine:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients aged 18 years or older with clinically confirmed diagnosis of chorea associated with HD 2.Patients whose baseline total maximal chorea (TMC) score = 8 3.Patients who are deutetrabenazine-naïve before study entry or didn’t receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD 4.Patients who have provided written consent for the use of personal and medical information for study purposes

Exclusion criteria

Exclusion criteria: 1.Patients who have an unstable or serious medical or psychiatric illness at baseline 2.Patients with any history of suicidality, untreated or inadequately treated depression 3.Patients with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias 4.Patients who received reserpine within 20 days of deutetrabenazine treatment initiation 5.Patients who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation 6.Patients who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation 7.Patients unable to provide a written consent for the study 8.Patients who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study

Design outcomes

Primary

Measure	Time frame
Unified Huntington’s Disease Rating Scale (UHDRS) total maximal chorea (TMC) score;	—

Secondary

Measure	Time frame
Adverse event occurrence;	—

Countries

China

Contacts

Public ContactHuifang Shang

West china hospital, Sichuan University

hfshang2002@163.com+86 189 8060 2127

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026